{"id":38031,"date":"2025-10-01T10:21:47","date_gmt":"2025-10-01T08:21:47","guid":{"rendered":"https:\/\/immunostep.com\/?p=38031"},"modified":"2025-10-01T10:21:47","modified_gmt":"2025-10-01T08:21:47","slug":"cd19-car-t-in-acute-lymphoblastic-leukaemia","status":"publish","type":"post","link":"https:\/\/immunostep.com\/es\/2025\/10\/01\/cd19-car-t-in-acute-lymphoblastic-leukaemia\/","title":{"rendered":"CD19 CAR-T in Acute Lymphoblastic Leukaemia"},"content":{"rendered":"<p><strong>CD19-targeted <a href=\"https:\/\/immunostep.com\/immunology\/car-t\/\">CAR-T cells<\/a><\/strong> have transformed the management of <strong>acute<\/strong> <strong>lymphoblastic leukaemia (ALL)<\/strong>, especially in refractory or relapsed paediatric and young adult patients. Accumulated clinical experience has demonstrated complete <strong>remissions in over 80% of cases<\/strong>, but persistent relapses, toxicity and production logistics remain significant challenges.<\/p>\n<p>This article discusses the latest advances and emerging strategies that are shaping the evolution of CAR-T therapies in ALL.<\/p>\n<h3>Antigen escape: beyond CD19<\/h3>\n<p><strong>Escape through loss or modulation of the CD19<\/strong> antigen remains the most common cause of relapse after CAR-T therapy. To address this, current research is focusing on:<\/p>\n<ul>\n<li><strong>Biespecific CAR-T (CD19\/CD22, CD19\/CD20):<\/strong> recent clinical trials show a significant reduction in relapses due to tumour escape and better control of minimal residual disease.<\/li>\n<li><strong>T-cell engager-secreting CAR-T:<\/strong> these allow endogenous T lymphocytes to be recruited against B cells that express other antigens, prolonging immune pressure.<\/li>\n<li><strong>Epigenetic editing and reprogramming of tumour lymphocytes:<\/strong> experimental strategies to prevent phenotypic plasticity and CD19 loss.<\/li>\n<\/ul>\n<p>These approaches are demonstrating that the combination of multiple targets and synergistic mechanisms may be key to overcoming resistance.<\/p>\n<h3>Persistence and functional improvement<\/h3>\n<p>The durability of the response remains a critical factor. Among the most promising strategies are:<\/p>\n<ul>\n<li><strong>Fourth-generation CAR-T (\u2018armoured\u2019):<\/strong> cells that secrete cytokines such as IL-18 or IL-15, promoting sustained expansion and activation of surrounding immune cells.<\/li>\n<li><strong>Memory phenotype optimisation:<\/strong> the selection of na\u00efve or central memory T cells improves persistence and reduces chronic T cell dysfunction.<\/li>\n<li><strong>Metabolic reprogramming:<\/strong> cellular modifications that enable more efficient metabolism, improving CAR-T survival in adverse microenvironments.<\/li>\n<\/ul>\n<p>The goal is to achieve a prolonged response without increasing toxicity, maintaining efficacy even in complex tumour environments.<\/p>\n<h3>Toxicity and safety strategies<\/h3>\n<p>Cytokine release syndrome (CRS) and associated neurotoxicity (ICANS) remain significant clinical challenges. Current approaches include:<\/p>\n<ul>\n<li><strong>CAR-T with suicide or switchable switches:<\/strong> these allow cell activity to be stopped in the event of severe toxicity.<\/li>\n<li><strong>Switchable CAR-T:<\/strong> real-time controllable activation systems, optimising safety and efficacy.<\/li>\n<li><strong>In vivo therapies:<\/strong> use of lipid nanoparticles (LNPs) that allow CAR-T to be generated directly in the patient, avoiding lymphodepletion and reducing production times.<\/li>\n<\/ul>\n<p>These strategies promise to improve tolerance without compromising antitumour activity.<\/p>\n<h3>Expansion of indications and accessibility<\/h3>\n<p>The potential of CD19 CAR-T cells goes beyond ALL:<\/p>\n<ul>\n<li><strong>Autoimmune diseases:<\/strong> preliminary studies in systemic lupus erythematosus and multiple sclerosis show that CAR-T cells can \u2018reset\u2019 the immune system.<\/li>\n<li><strong>Allogeneic (\u2018off-the-shelf\u2019) CAR-T:<\/strong> these enable standardised treatments, reduce costs and production time, and facilitate global access to advanced therapies.<\/li>\n<li><strong>Integration with immunomodulators:<\/strong> combination with checkpoint inhibitors or tumour microenvironment modulators can improve efficacy and reduce escape.<\/li>\n<\/ul>\n<p>These advances could redefine the therapeutic strategy in haematology and autoimmunity, transforming CAR-T from a last-line resource to a more accessible and versatile treatment.<\/p>\n<h3>Challenges and future prospects<\/h3>\n<p>Despite the clinical impact, challenges remain to be resolved:<\/p>\n<ul>\n<li><strong>Antigenic escape mechanisms and clonality of ALL.<\/strong><\/li>\n<li><strong>Optimisation of persistence and T memory without increasing toxicity.<\/strong><\/li>\n<li><strong>Scalability and logistics:<\/strong> faster, safer and more economical production for widespread use.<\/li>\n<li><strong>Combination with other therapies:<\/strong> integrating CAR-T with immune modulators or specific targeted treatments.<\/li>\n<\/ul>\n<p>Researchers are developing safer, longer-lasting, and more universal therapies, bringing cell immunotherapy closer to all patients with refractory or high-risk ALL.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>CD19-targeted CAR-T cells have transformed the management of acute lymphoblastic leukaemia (ALL), especially in refractory or relapsed paediatric and young adult patients. Accumulated clinical experience has demonstrated complete remissions in over 80% of cases, but persistent relapses, toxicity and production logistics remain significant challenges. This article discusses the latest advances and emerging strategies that are [&hellip;]<\/p>\n","protected":false},"author":225,"featured_media":38032,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[2033],"tags":[2342,2343,2285,2031,2341,2104,2123,2121,2151,2159],"class_list":["post-38031","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-immunology","tag-all","tag-autoimmune","tag-canceer-treatment","tag-car-t","tag-car-t-cells","tag-cd19","tag-production","tag-research","tag-t-cell-responses","tag-therapy"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>CD19 CAR-T in Acute Lymphoblastic Leukaemia | Immunostep Biotech<\/title>\n<meta name=\"description\" content=\"CD19 CAR-T in ALL: advanced review of resistance mechanisms, toxicity, and emerging strategies in refractory or relapsed leukemia.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/immunostep.com\/2025\/10\/01\/cd19-car-t-in-acute-lymphoblastic-leukaemia\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CD19 CAR-T in Acute Lymphoblastic Leukaemia | Immunostep Biotech\" \/>\n<meta property=\"og:description\" content=\"CD19 CAR-T in ALL: advanced review of resistance mechanisms, toxicity, and emerging strategies in refractory or relapsed leukemia.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/immunostep.com\/2025\/10\/01\/cd19-car-t-in-acute-lymphoblastic-leukaemia\/\" \/>\n<meta property=\"og:site_name\" content=\"Immunostep Biotech\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/immunostepsl\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-01T08:21:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/immunostep.com\/wp-content\/uploads\/2025\/10\/CD19-CAR-T-in-ALL.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1021\" \/>\n\t<meta property=\"og:image:height\" content=\"409\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u00c1ngela Cabestrero\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@Immunostep\" \/>\n<meta name=\"twitter:site\" content=\"@Immunostep\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u00c1ngela Cabestrero\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/immunostep.com\/2025\/10\/01\/cd19-car-t-in-acute-lymphoblastic-leukaemia\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/immunostep.com\/2025\/10\/01\/cd19-car-t-in-acute-lymphoblastic-leukaemia\/\"},\"author\":{\"name\":\"\u00c1ngela Cabestrero\",\"@id\":\"https:\/\/immunostep.com\/#\/schema\/person\/6f7086a7900eb41588a2465bcae5f427\"},\"headline\":\"CD19 CAR-T in Acute Lymphoblastic Leukaemia\",\"datePublished\":\"2025-10-01T08:21:47+00:00\",\"dateModified\":\"2025-10-01T08:21:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/immunostep.com\/2025\/10\/01\/cd19-car-t-in-acute-lymphoblastic-leukaemia\/\"},\"wordCount\":527,\"publisher\":{\"@id\":\"https:\/\/immunostep.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/immunostep.com\/2025\/10\/01\/cd19-car-t-in-acute-lymphoblastic-leukaemia\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/immunostep.com\/wp-content\/uploads\/2025\/10\/CD19-CAR-T-in-ALL.jpg\",\"keywords\":[\"ALL\",\"autoimmune\",\"canceer treatment\",\"CAR T\",\"CAR-T cells\",\"CD19\",\"production\",\"research\",\"t cell responses\",\"therapy\"],\"articleSection\":[\"Immunology\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/immunostep.com\/2025\/10\/01\/cd19-car-t-in-acute-lymphoblastic-leukaemia\/\",\"url\":\"https:\/\/immunostep.com\/2025\/10\/01\/cd19-car-t-in-acute-lymphoblastic-leukaemia\/\",\"name\":\"CD19 CAR-T in Acute Lymphoblastic Leukaemia | Immunostep Biotech\",\"isPartOf\":{\"@id\":\"https:\/\/immunostep.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/immunostep.com\/2025\/10\/01\/cd19-car-t-in-acute-lymphoblastic-leukaemia\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/immunostep.com\/2025\/10\/01\/cd19-car-t-in-acute-lymphoblastic-leukaemia\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/immunostep.com\/wp-content\/uploads\/2025\/10\/CD19-CAR-T-in-ALL.jpg\",\"datePublished\":\"2025-10-01T08:21:47+00:00\",\"dateModified\":\"2025-10-01T08:21:47+00:00\",\"description\":\"CD19 CAR-T in ALL: advanced review of resistance mechanisms, toxicity, and emerging strategies in refractory or relapsed leukemia.\",\"breadcrumb\":{\"@id\":\"https:\/\/immunostep.com\/2025\/10\/01\/cd19-car-t-in-acute-lymphoblastic-leukaemia\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/immunostep.com\/2025\/10\/01\/cd19-car-t-in-acute-lymphoblastic-leukaemia\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/immunostep.com\/2025\/10\/01\/cd19-car-t-in-acute-lymphoblastic-leukaemia\/#primaryimage\",\"url\":\"https:\/\/immunostep.com\/wp-content\/uploads\/2025\/10\/CD19-CAR-T-in-ALL.jpg\",\"contentUrl\":\"https:\/\/immunostep.com\/wp-content\/uploads\/2025\/10\/CD19-CAR-T-in-ALL.jpg\",\"width\":1021,\"height\":409,\"caption\":\"Female lab technician working with strains of bacteria grown in petri dishes.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/immunostep.com\/2025\/10\/01\/cd19-car-t-in-acute-lymphoblastic-leukaemia\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/immunostep.com\/es\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CD19 CAR-T in Acute Lymphoblastic Leukaemia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/immunostep.com\/#website\",\"url\":\"https:\/\/immunostep.com\/\",\"name\":\"Immunostep Biotech\",\"description\":\"Innovating to deliver high-performance technology for Research and Diagnosis\",\"publisher\":{\"@id\":\"https:\/\/immunostep.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/immunostep.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/immunostep.com\/#organization\",\"name\":\"Immunostep Biotech\",\"url\":\"https:\/\/immunostep.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/immunostep.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/immunostep.com\/wp-content\/uploads\/2021\/10\/logo-web-color.png\",\"contentUrl\":\"https:\/\/immunostep.com\/wp-content\/uploads\/2021\/10\/logo-web-color.png\",\"width\":1299,\"height\":591,\"caption\":\"Immunostep Biotech\"},\"image\":{\"@id\":\"https:\/\/immunostep.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/immunostepsl\/\",\"https:\/\/x.com\/Immunostep\",\"https:\/\/www.linkedin.com\/company\/immunostepsl\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/immunostep.com\/#\/schema\/person\/6f7086a7900eb41588a2465bcae5f427\",\"name\":\"\u00c1ngela Cabestrero\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/immunostep.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/378033e78b9b0300f6f50aeac830c5cf?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/378033e78b9b0300f6f50aeac830c5cf?s=96&d=mm&r=g\",\"caption\":\"\u00c1ngela Cabestrero\"},\"url\":\"https:\/\/immunostep.com\/es\/author\/acabestrero\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CD19 CAR-T in Acute Lymphoblastic Leukaemia | Immunostep Biotech","description":"CD19 CAR-T in ALL: advanced review of resistance mechanisms, toxicity, and emerging strategies in refractory or relapsed leukemia.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/immunostep.com\/2025\/10\/01\/cd19-car-t-in-acute-lymphoblastic-leukaemia\/","og_locale":"es_ES","og_type":"article","og_title":"CD19 CAR-T in Acute Lymphoblastic Leukaemia | Immunostep Biotech","og_description":"CD19 CAR-T in ALL: advanced review of resistance mechanisms, toxicity, and emerging strategies in refractory or relapsed leukemia.","og_url":"https:\/\/immunostep.com\/2025\/10\/01\/cd19-car-t-in-acute-lymphoblastic-leukaemia\/","og_site_name":"Immunostep Biotech","article_publisher":"https:\/\/www.facebook.com\/immunostepsl\/","article_published_time":"2025-10-01T08:21:47+00:00","og_image":[{"width":1021,"height":409,"url":"https:\/\/immunostep.com\/wp-content\/uploads\/2025\/10\/CD19-CAR-T-in-ALL.jpg","type":"image\/jpeg"}],"author":"\u00c1ngela Cabestrero","twitter_card":"summary_large_image","twitter_creator":"@Immunostep","twitter_site":"@Immunostep","twitter_misc":{"Escrito por":"\u00c1ngela Cabestrero","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/immunostep.com\/2025\/10\/01\/cd19-car-t-in-acute-lymphoblastic-leukaemia\/#article","isPartOf":{"@id":"https:\/\/immunostep.com\/2025\/10\/01\/cd19-car-t-in-acute-lymphoblastic-leukaemia\/"},"author":{"name":"\u00c1ngela Cabestrero","@id":"https:\/\/immunostep.com\/#\/schema\/person\/6f7086a7900eb41588a2465bcae5f427"},"headline":"CD19 CAR-T in Acute Lymphoblastic Leukaemia","datePublished":"2025-10-01T08:21:47+00:00","dateModified":"2025-10-01T08:21:47+00:00","mainEntityOfPage":{"@id":"https:\/\/immunostep.com\/2025\/10\/01\/cd19-car-t-in-acute-lymphoblastic-leukaemia\/"},"wordCount":527,"publisher":{"@id":"https:\/\/immunostep.com\/#organization"},"image":{"@id":"https:\/\/immunostep.com\/2025\/10\/01\/cd19-car-t-in-acute-lymphoblastic-leukaemia\/#primaryimage"},"thumbnailUrl":"https:\/\/immunostep.com\/wp-content\/uploads\/2025\/10\/CD19-CAR-T-in-ALL.jpg","keywords":["ALL","autoimmune","canceer treatment","CAR T","CAR-T cells","CD19","production","research","t cell responses","therapy"],"articleSection":["Immunology"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/immunostep.com\/2025\/10\/01\/cd19-car-t-in-acute-lymphoblastic-leukaemia\/","url":"https:\/\/immunostep.com\/2025\/10\/01\/cd19-car-t-in-acute-lymphoblastic-leukaemia\/","name":"CD19 CAR-T in Acute Lymphoblastic Leukaemia | Immunostep Biotech","isPartOf":{"@id":"https:\/\/immunostep.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/immunostep.com\/2025\/10\/01\/cd19-car-t-in-acute-lymphoblastic-leukaemia\/#primaryimage"},"image":{"@id":"https:\/\/immunostep.com\/2025\/10\/01\/cd19-car-t-in-acute-lymphoblastic-leukaemia\/#primaryimage"},"thumbnailUrl":"https:\/\/immunostep.com\/wp-content\/uploads\/2025\/10\/CD19-CAR-T-in-ALL.jpg","datePublished":"2025-10-01T08:21:47+00:00","dateModified":"2025-10-01T08:21:47+00:00","description":"CD19 CAR-T in ALL: advanced review of resistance mechanisms, toxicity, and emerging strategies in refractory or relapsed leukemia.","breadcrumb":{"@id":"https:\/\/immunostep.com\/2025\/10\/01\/cd19-car-t-in-acute-lymphoblastic-leukaemia\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/immunostep.com\/2025\/10\/01\/cd19-car-t-in-acute-lymphoblastic-leukaemia\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/immunostep.com\/2025\/10\/01\/cd19-car-t-in-acute-lymphoblastic-leukaemia\/#primaryimage","url":"https:\/\/immunostep.com\/wp-content\/uploads\/2025\/10\/CD19-CAR-T-in-ALL.jpg","contentUrl":"https:\/\/immunostep.com\/wp-content\/uploads\/2025\/10\/CD19-CAR-T-in-ALL.jpg","width":1021,"height":409,"caption":"Female lab technician working with strains of bacteria grown in petri dishes."},{"@type":"BreadcrumbList","@id":"https:\/\/immunostep.com\/2025\/10\/01\/cd19-car-t-in-acute-lymphoblastic-leukaemia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/immunostep.com\/es\/"},{"@type":"ListItem","position":2,"name":"CD19 CAR-T in Acute Lymphoblastic Leukaemia"}]},{"@type":"WebSite","@id":"https:\/\/immunostep.com\/#website","url":"https:\/\/immunostep.com\/","name":"Immunostep Biotech","description":"Innovating to deliver high-performance technology for Research and Diagnosis","publisher":{"@id":"https:\/\/immunostep.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/immunostep.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/immunostep.com\/#organization","name":"Immunostep Biotech","url":"https:\/\/immunostep.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/immunostep.com\/#\/schema\/logo\/image\/","url":"https:\/\/immunostep.com\/wp-content\/uploads\/2021\/10\/logo-web-color.png","contentUrl":"https:\/\/immunostep.com\/wp-content\/uploads\/2021\/10\/logo-web-color.png","width":1299,"height":591,"caption":"Immunostep Biotech"},"image":{"@id":"https:\/\/immunostep.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/immunostepsl\/","https:\/\/x.com\/Immunostep","https:\/\/www.linkedin.com\/company\/immunostepsl\/"]},{"@type":"Person","@id":"https:\/\/immunostep.com\/#\/schema\/person\/6f7086a7900eb41588a2465bcae5f427","name":"\u00c1ngela Cabestrero","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/immunostep.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/378033e78b9b0300f6f50aeac830c5cf?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/378033e78b9b0300f6f50aeac830c5cf?s=96&d=mm&r=g","caption":"\u00c1ngela Cabestrero"},"url":"https:\/\/immunostep.com\/es\/author\/acabestrero\/"}]}},"_links":{"self":[{"href":"https:\/\/immunostep.com\/es\/wp-json\/wp\/v2\/posts\/38031"}],"collection":[{"href":"https:\/\/immunostep.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/immunostep.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/immunostep.com\/es\/wp-json\/wp\/v2\/users\/225"}],"replies":[{"embeddable":true,"href":"https:\/\/immunostep.com\/es\/wp-json\/wp\/v2\/comments?post=38031"}],"version-history":[{"count":1,"href":"https:\/\/immunostep.com\/es\/wp-json\/wp\/v2\/posts\/38031\/revisions"}],"predecessor-version":[{"id":38034,"href":"https:\/\/immunostep.com\/es\/wp-json\/wp\/v2\/posts\/38031\/revisions\/38034"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/immunostep.com\/es\/wp-json\/wp\/v2\/media\/38032"}],"wp:attachment":[{"href":"https:\/\/immunostep.com\/es\/wp-json\/wp\/v2\/media?parent=38031"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/immunostep.com\/es\/wp-json\/wp\/v2\/categories?post=38031"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/immunostep.com\/es\/wp-json\/wp\/v2\/tags?post=38031"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}